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Background: Analysis of the human genome has revealed that as much as an order of magnitude more of the
genomic sequence is transcribed than accounted for by the predicted and characterized genes. A number of these
transcripts are alternatively spliced forms of known protein coding genes; however, it is becoming clear that many
of them do not necessarily correspond to a functional protein.
Results: In this study we analyze alternative splicing isoforms of human gene products that are unambiguously
identified by mass spectrometry and compare their properties with those of isoforms of the same genes for which
no peptide was found in publicly available mass spectrometry datasets. We analyze them in detail for the presence
of uninterrupted functional domains, active sites as well as the plausibility of their predicted structure. We report
how well each of these strategies and their combination can correctly identify translated isoforms and derive a
lower limit for their specificity, that is, their ability to correctly identify non-translated products.
Conclusions: The most effective strategy for correctly identifying translated products relies on the conservation of
active sites, but it can only be applied to a small fraction of isoforms, while a reasonably high coverage, sensitivity
and specificity can be achieved by analyzing the presence of non-truncated functional domains. Combining the
latter with an assessment of the plausibility of the modeled structure of the isoform increases both coverage and
specificity with a moderate cost in terms of sensitivity.
Background
Alternative splicing (AS) is a mechanism used by cells to
diversify the proteins produced by a gene. Estimates of
the amount of AS in human have risen dramatically
over recent years, especially since the advent of novel
high-throughput sequencing technologies [1-3], reaching
up to the 95% of the multi-exon genes [4].
While the role of AS in expanding the functional
complexity of a genome is established, less clear is
whether all generated transcripts do indeed encode
functional proteins and therefore expand the coding
potential of a genome. Cases are known of events that
produce splicing variants (isoforms) showing novel and
sometimes unexpected structural and functional proper-
ties [5,6]. On the other hand, evidence from analysis of
sequences, structures and homology models suggest that
many AS isoforms, even if detectable at the
transcriptomic level, might not encode functional pro-
teins because, for example, they lack important func-
tional regions and/or seem to correspond to incomplete
structures [7,8].
The overwhelming majority of AS evidence is based
on transcriptomic data; therefore, a proof that the spli-
cing product is eventually translated and can fold into a
functional protein is generally missing. Nonetheless, it is
evident that knowing whether or not an isoform
observed at the transcriptional level does indeed corre-
spond to a functional protein is relevant for both theo-
retical and practical reasons. Since it is practically
impossible to identify negative cases - examples where
one isoform certainly does not correspond to a func-
tional protein - this is a scenario where we can only
resort to computational methods for obtaining a prob-
abilistic estimate of the likelihood that a protein is
functional.
Computational method inferences are difficult to vali-
date in the absence of a clearly defined negative set, but
one can still assess their sensitivity in identifying
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example, they have been unambiguously identified in
proteomic experiments. Although the detection of a
peptide identifying an isoform is not conclusive for its
functional characterization, it does imply that the corre-
sponding transcript is translated into a protein likely to
fold and be produced at sufficient levels to be detected,
a n dt h e r e f o r es t r o n g l ys u g g e s t st h a ti ti su n l i k e l yt ob e
non-protein coding. This concept has been applied in
the past, in small scale, to data by Tanner and cowor-
kers [9], who found 16 human genes for which two dif-
ferent isoforms could be unambiguously identified by
mass spectrometry (MS). A larger scale systematic ana-
lysis of isoform proteomic identification based on MS
data performed for the fruit fly [10] led to the identifica-
tion of AS events that could be confirmed at the protein
level for 130 genes. The limited coverage of proteomics
data, still far from the level of completeness provided by
transcript expression analysis platforms [10], is the main
reason behind the relatively low number of genes identi-
fied in both the aforementioned studies.
In this work, we take advantage of MS data for con-
structing a dataset composed of human isoforms unam-
biguously identified by MS (AS positive (ASPos) dataset)
and use several computational methods to compare
their properties with those of isoforms for which no
matching peptide can be found in MS public database
(unknown dataset). In particular, we study: their struc-
tural plausibility, based on structural models by homol-
ogy; the presence of complete domains, based on Pfam
domain definitions [11]; and the presence of functional
sites, such as catalytic sites, based on SwissProt anno-
tated features [12].
The results obtained with this positive dataset, which
we used as a benchmark, allowed us to estimate how
much each of the methodologies listed above can help
in identifying translated isoforms. There is clearly a
trade-off between the coverage achieved by each method
(for example, the presence of a functional domain is
more frequent than the presence of annotated functional
sites) and their reliability in predicting the likelihood
that the isoform is translated into a product. We used
our positive set to estimate the fraction of false nega-
tives detected by each method separately and by their
combinations. In order to validate our conclusions, we
also built two additional datasets, one containing ORFs
obtained from the translation of non-coding transcripts
(negative dataset) and one including all products of
genes not undergoing AS and for which experimental
evidence is available by MS (the noASPos dataset). The
first dataset is somewhat artificial since its elements are
only selected on the basis of the absence of termination
codons in a sufficiently long ORF (at least 100 amino acids
long) and is not really representative of realistic cases.
On the other hand, the unknown dataset might con-
tain isoforms that are not observed because they are
only present at specific times or in specific cell types
a n di s o f o r m st h a ta r en o td e t ected for technical reason
by MS. This notwithstanding, the analysis of both
datasets can be used to obtain an estimate of the false
positive rate of the computational techniques.
Results obtained by considering the ASPos and
unknown datasets show that, as expected, the single
method with highest sensitivity - that is, the ability to
correctly identify translated products - can be achieved
by relying on the conservation of features annotated in
SwissProt in the isoform, but this is not very frequent
(coverage of about 14%), while a reasonably high cover-
age (81%), a good sensitivity (95%) and a specificity above
4 0 %c a nb ea c h i e v e db ya n a l y z i n gt h ep r e s e n c eo fn o n -
truncated Pfam domains. Combining the latter with an
assessment of the plausibility of the modeled structure of
the isoform increases the coverage by another 8%, with a
decrease in sensitivity, but in this case the lower estimate
for the specificity increases by at least 2%.
When the artificial non-coding dataset is used as a
negative set, the results do not change substantially.
Clearly, no SwissProt annotations exist for these tran-
scripts, the presence of non-truncated Pfam domains
still has the highest coverage (81%) and sensitivity
(95%), with a specificity of around 30%. Also, the combi-
nation of structural plausibility and the presence of non-
truncated Pfam domains produces a similar picture with
coverage, sensitivity and specificity values of 87%, 93%
and 33%, respectively.
A different balance between specificity and sensitivity
can be required in different cases; therefore, we think
that the results reported here can provide a useful guide
to prioritizing experiments for different purposes.
Results and discussion
Proteomics technology can provide experimental evi-
dence that a specific isoform is expressed, translated
and sufficiently stable to be detected in vivo, although,
unfortunately, it cannot be used to exclude the presence
of a protein, nor can any other experimental technique
provide such information. Nevertheless, the analysis of
proteomic datasets can offer a repertoire of isoforms
whose products are certainly present in the cell. Proteo-
mics experiments provide a large amount of data, which
are available in specialized databases such as PeptideA-
tlas [13] in the form of peptides with unambiguous
mapping to protein sequences. In order to be able to
detect the presence of a specific isoform in the midst of
the whole spectrum of possible products of a gene, we
first need to identify those isoform regions that are spe-
cific for one isoform, that is, that do not map to any
other isoform of the same gene [14].
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15,914 produce more than one isoform, and are there-
fore subject to AS. We did not include in this dataset
those isoforms annotated as non-protein coding by
Ensembl, and those differing only in their UTRs at the
5’ or 3’ end (therefore having identical coding regions),
and ended up with 60,568 isoforms. In this group of
alternative transcripts, we identified all regions (whole
exons or exon portions) of each gene that are included
in only one isoform (Figure 1). The detection of pep-
tides mapping to such specific regions in MS experi-
ments allows the unambiguous identification of the
translation of the corresponding transcripts. PeptideA-
tlas human build peptides (May 2010) were mapped to
the exons of these isoforms and classified as specific or
unspecific accordingly. A total of 1,124 isoforms (from
1,025 genes) are identified by at least one specific pep-
tide, and represent the set of isoforms whose existence
is confirmed at the protein level. This figure is some-
what different from that reported in [14], where specific
transcripts for 3,059 human alternatively spliced genes
were identified using PeptideAtlas peptides, but this was
expected since we used a more up-to-date release of
PeptideAtlas in which the peptide mapping criteria were
more stringent.
We focused our analysis on those genes having at least
one isoform unequivocally identified by PeptideAtlas
peptides and at least one other isoform for which no
peptide mapping to its specific regions was found and
that were predicted by PeptideSieve [16] to be detectable
by the most popular current MS technologies (this being
due to their charge, hydrophobicity, mass, secondary
structure, and so on). When more than one ASPos or
unknown isoform were present for a gene, we selected
only the shortest and longest ones, respectively. We also
verified that the results would not be affected if we were
t ou s ei s o f o r m si d e n t i f i e db ya tl e a s tt w oo rm o r ep e p -
tides (data not shown).
We also built a dataset containing the products of all
genes that do not undergo AS and that are identified by
at least one peptide present in PeptideAtlas and a data-
set built by translating ORFs present in processed tran-
scripts annotated as non-coding in Ensembl (see
Materials and methods).
In conclusion, our datasets include 555 isoforms iden-
tified by MS (ASPos dataset), 555 isoforms correspond-
ing to the same genes but for which no specific peptide
is present in PeptideAtlas (unknown dataset), 865 pro-
ducts of genes that do not undergo AS (noASPos data-
set) and 555 translated sequences from non-coding
transcripts (negative dataset).
Our unknown dataset doubtlessly includes isoforms
whose product is not detected since it is present only in
specific tissues, cell cycle phases, developmental stages,
or in the presence of specific stimuli, but a certain frac-
tion can produce non-protein coding transcripts.
Our aim is to determine how many of the isoforms in
the ASPos dataset that are identified as true products of
a regulated AS event can be detected by different com-
putational methods in order to evaluate their sensitivity.
For the reason described above, the unknown set can
only be used to estimate the lower limit of the specifi-
city of the methods, while the negative dataset does not
suffer this problem but is less representative of a real
situation, even though we obtained the sequence by
translating processed transcripts rather than random
genomic sequences.
Positive isoforms are predicted to be structurally more
plausible than unknown isoforms
Arguably, a considerable amount of non-functional AS
will lead to polypeptide sequences that can not fold in a
Figure 1 Scheme of possible scenarios for comparing different isoforms. Only peptides mapping in the products of shaded regions are
considered specific.
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We cannot exclude that a stable conformation can be
the result of profound structural rearrangements or of
the establishment of stabilizing interactions with a bind-
ing partner. Such cases are very hard to identify, but
apparently not very frequent [5,6].
Here we predicted the structure of all the isoforms of
the ASPos and noASPos datasets for which a suitable
structural template could be found and carefully analyzed
the resulting models according to several criteria. We
estimated how well packed the protein model is and the
extent to which hydrophobic surface is exposed to sol-
vent with respect to the average single domain proteins
i nt h ed a t a b a s eo fs o l v e dp r o t e i ns t r u c t u r e sa n dt ot h e
template used to build the model (see Materials and
methods). We also assessed whether insertions and dele-
tions with respect to the structural template, when pre-
sent, could be accommodated within the modeled
structure. In particular, we flagged as ‘unlikely’ cases
where a deletion would imply connectivity between two
residues that are too far away in space and where inser-
tions would occur in the well packed core of the protein.
The detailed pipeline for model building is described
in the Materials and methods section. We were able to
model 230 isoforms from the noASPos dataset, 147
from the ASPos dataset, 145 from the unknown dataset
and 84 from the negative dataset, with coverage (that is,
the fraction of protein sequence that can be modeled) of
at least 90%.
The majority (134; 91%) of modeled isoforms from the
ASPos dataset are structurally consistent. Difficult to
accommodate deletions and/or insertions with respect
to the template are present for nine isoforms from the
positive dataset (6%), while five show a non-optimal
packing of their interior (the two cases can obviously
occur in the same isoform). The corresponding numbers
for the noASPos dataset are similar (88% with a plausi-
ble structure, 9 isoforms with difficult to accommodate
deletions/insertions corresponding to about 4% of the
total and 18 with non-optimal packing corresponding to
8% of the total). On the other hand, the fraction of
viable models is remarkably smaller for the negative (40;
48%) and unknown dataset isoforms (69; 48%). The
negative dataset includes 13 models with difficult to
accommodate deletions/insertions and 32 models with
non-optimal packing. In 64 cases the models of the
unknown dataset show non-optimal packing and in 10
they also have difficult to accommodate deletions/
insertions.
Functional domains are more often truncated in unknown
isoforms than in positive ones
AS can remove whole protein domains, but tend not to
occur within domains [17]. While this is not an absolute
rule, it is reasonable to assume that a substantial
amount of isoforms where at least one domain is trun-
cated by a splicing event correspond to non-protein
coding transcripts.
To verify how well this criterion performs in real
cases, we used the definition of domains in the Pfam
database [11]. Each Pfam domain is described by a hid-
den Markov model (HMM) built on the seed example
sequences for that domain. Different isoforms of the
same gene can carry different sets of domains [18,19].
On the other hand, a domain that is truncated in an iso-
form is more likely to be the result of incorrect splicing
than of a regulated event. As described in Materials and
methods, a domain is considered truncated if the iso-
form sequence matches less than 70% of its length.
Most isoforms of the noASPos and ASPos datasets
(83% and 86%, respectively) only include complete Pfam
domains, and only 5% contain truncated Pfam domains.
The situation is drastically different for the unknown
and negative datasets, where 41% and 50% of the iso-
forms only contain complete Pfam domains, respec-
tively, and 42% and 36% include at least one truncated
Pfam domain.
It should be mentioned that more Pfam domains are
found in isoforms of the ASPos dataset than the
unknown one (2.43 domains on average versus 1.63).
This could be attributed to the fact that these isoforms
tend to be longer than the unknown ones (average
length 694 amino acids versus 345). On the other hand,
our data indicate that the length has little or no impact
on the number of truncated domains. The average
length of proteins included in the PDB database [20] is
606 amino acids and the percentage of proteins with
truncated Pfam domains is only 14%, much lower than
what we observe in our unknown dataset, and the per-
centage of truncated Pfam domains in these proteins is
independent of the length (data not shown). Similarly,
sequences in our noASPos dataset, whose average length
( 4 3 6 )i sc o m p a r a b l ew i t ht h a to fm e m b e r so ft h e
unknown (345) and negative datasets (485), include a
truncated domain in only 5% of cases (compared with
42% and 36% for the unknown and negative datasets).
Although we cannot exclude that the length of the tran-
scripts might affect the results to a minor extent, we
believe that in any case, the presence of a truncated
domain, whatever the reason, is an indication of a lack
or impairment of the associated function.
Functional features are rarely disrupted in positive
isoforms
We verified whether AS would remove existing anno-
tated active sites present in other isoforms of the same
gene in the ASPos and unknown datasets. A similar
p r o c e d u r ec a n n o tb ea p p l i e dt ot h en e g a t i v ed a t a s e t ,
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nor, obviously, to the noASPos dataset, where no AS
occurs.
In several entries of our ASPos dataset, the annotation
for an active site (80 genes) is present in the Swiss-Prot
database [12]. Active sites are present in both isoforms
of the positive and unknown dataset in only 60% of
cases. In all other cases, the isoform of the unknown
dataset (which is not identified by a specific peptide in
PeptideAtlas) does not retain the active sites. In a single
case a functional site is found in the unknown dataset
isoform (Ensembl ID: ENSP00000359932) but not in the
associated positive isoform (ENSP00000359935). In this
case, positive and unknown isoforms have a radically
different amino acid sequence after residue 114, due to
the usage of different exons after the initial shared por-
tion (for this reason these two isoforms are associated
with different SwissProt IDs, FPGT_HUMAN and
TNI3K_HUMAN, respectively) and have a different bio-
logical function (the former is a fucose-1-phosphate
guanylyltransferase, the latter a serine/threonine-protein
kinase). Therefore, in this particular case, the loss of
functional sites is due to a radical functional change.
Transcription levels of the isoforms in different datasets
Isoform-specific expression can be estimated by means
of recently developed microarray platforms that target
all exons of a gene or (a subset of) exon-exon junctions.
The Affymetrix Exon arrays [21] are high-density chips
in which probe sets (composed by at least four probes)
were designed for all exons in Ensembl. This platform
proved to be very accurate and sensitive in the detection
of AS events and is routinely used for the study of cellu-
lar processes in healthy or disease conditions. Expres-
sion data from 11 adult human tissues are publicly
available from the Affymetrix website, and offer a valu-
able resource for the study of exon-level expression of
human isoforms. The distribution of the expression level
of the transcripts present in the ASPos, noASPos and
unknown datasets are shown in Figure 2.
As can be appreciated from Figure 2, the isoforms in
the unknown dataset have a lower level of normalized
expression of specific exons than those in the ASPos
and noASPos datasets. This notwithstanding, the overlap
between the distributions is rather high (around 70%).
Some of the unknown isoforms whose transcripts are
expressed at lower levels might correspond to products
present in limited amounts and less likely to be detected
by MS, or they might be due to splicing errors, which
are expected to happen at low frequency. On the other
hand, a high percentage of non-detected isoforms are
expressed at levels similar to those of the positive data-
sets and the lack of their detection points to the possibi-
lity that they do not produce functional proteins.
Statistical significance of different criteria
Figure 3 and Table 1 summarize results on coverage,
accuracy, sensitivity and the lower estimate of the speci-
ficity of the criteria described above as well as of their
union and intersection.
There is an obvious trade-off between coverage and
accuracy. Isoforms that preserve the active sites, that
contain only non-truncated Pfam domains and that are
structurally plausible are very likely to be translated in
functional products (80% accuracy), although this com-
bination of features is only observed in a small fraction
of the cases. On the other hand, a very good compro-
mise for predicting the functionality of an isoform is to
verify that it does not contain interrupted Pfam domains
or has a plausible modeled structure. This would be
appropriate for most practical purposes and applicable
to almost 90% of the cases, providing an accuracy above
70% with a sensitivity and specificity of 93% and of at
least 44%, respectively. The detection of complete Pfam
domains, certainly easier to obtain in large scale ana-
lyses, has a high coverage and good sensitivity, although
its specificity is not very high. In practice, when an iso-
form contains an interrupted Pfam domain, it is very
likely not to be functional, while the detection of only
complete Pfam domains in an isoform, especially if pro-
duced by a transcript overlapping with a coding one, as
is the case for our non-coding dataset, is not very infor-
mative. The overall picture does not change when the
non-coding dataset is considered instead of the
unknown one (in which case, however, the conservation
of the active sites cannot be taken into account), as
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Figure 2 Distribution of expression level values for specific
exons of transcripts included in the noASPos, ASPos and
unknown datasets.
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Page 5 of 10Figure 3 Venn diagrams showing the number of isoforms predicted to be functional and unlikely to be functional according to each
method. (a-h) The number of isoforms predicted to be functional according to each method in the ASPos dataset (a), the noASPos dataset (c),
the unknown dataset (e) and the negative dataset (g) and the number of isoforms unlikely to be functional according to each method in the
ASPos dataset (b), the noASPos dataset (d), the unknown dataset (f) and the negative dataset (h). AS, preservation of active sites; Pfam,
completeness of Pfam domains; St, structural plausibility.
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The wealth of high throughput data that are continu-
ously being produced opens the way to the investigation
of relevant properties of living organisms and can be
effectively exploited in many instances. Cataloguing all
putative isoforms of genes is one such example,
although care should be taken since there is evidence
that not all isoforms identified at the transcriptional
level correspond to functional proteins [8].
The question that we address here - whether or not
an isoform is likely to be functional - is relevant but
unfortunately cannot be answered in a definite way by
experimental approaches. While the presence of a
functional protein in the cell can be demonstrated, it is
impossible to assess that a given peptide sequence is
not present or functional at any given time or in any
compartment of a cell or an organism. Computational
methods, provided they are properly assessed and eval-
uated, are therefore essential. We show here that dif-
ferent computational strategies and their combination
can be effectively used as proxies for assessing the like-
lihood that an isoform observed at the transcriptional
level does correspond to a functional protein product.
We believe that the estimate of the accuracy of differ-
ent computational strategies and of their different com-
bination provided here can be used for selecting
different strategies for different occasions. In some
cases, a higher rate of false positives might be preferable
t oah i g h e rn u m b e ro ff a l s en e g a t i v e s-f o re x a m p l e ,
when a specific gene of interest is being investigated
thoroughly - although even in this case prioritizing the
experiment taking advantage of computational estimates
can save time and resources.
Obviously, the impossibility of obtaining a true nega-
tive set implies that, while one can assess the ability of
the methods to detect translated isoforms - that is, the
percent of true positives and false negatives that they
predict - it is impossible at present to give a precise esti-
mate of how many false positives would result from any
computational analysis. This is a very difficult, or per-
haps impossible, problem to solve, but learning about
the ability of the analyzed strategies to detect most of
the truly translated isoforms and the lower estimate
of their specificity that we have provided here can be of
great help in understanding the functional repertoire
of higher eukaryote genomes. Clearly, the accumulation
of more and more proteomic data will allow even more
effective strategies to be devised.
Materials and methods
The datasets used in this analysis were all constructed
starting from the coding portion of the human genome
in Ensembl57 [15]. Out of the total number of Ensembl
protein coding genes (22,320), 6,406 genes are not
Table 1 Results of the statistical analysis with respect to the unknown dataset
Coverage TP TN FP FN Accuracy Sensitivity Specificity
AS 0.14 79 31 48 1 0.69 0.99 0.39
St 0.26 134 76 69 13 0.72 0.91 0.52
Pfam 0.81 480 165 227 23 0.72 0.95 0.41
AS U St 0.35 175 101 99 14 0.71 0.93 0.50
St U Pfam 0.89 490 203 257 35 0.71 0.93 0.44
AS U Pfam 0.85 485 186 250 24 0.71 0.95 0.43
AS U St U Pfam 0.92 494 221 272 36 0.70 0.93 0.45
AS ∩ St 0.06 38 6 18 0 0.71 1.00 0.25
St ∩ Pfam 0.18 124 38 39 1 0.80 0.99 0.49
AS ∩ Pfam 0.10 74 10 25 0 0.77 1.00 0.28
AS ∩ St ∩ Pfam 0.05 37 3 10 0 0.80 1.00 0.23
Coverage, accuracy, sensitivity and specificity of the different strategies and their combinations (U = union and ∩ = intersection) with respect to the unknown
dataset. AS, preservation of active sites; Pfam, completeness of Pfam domains; St, structural plausibility. The definition of the other parameters is reported in
Materials and methods. FN, false negative; FP, false positive; TN, true negative; TP, true positive.
Table 2 Results of the statistical analysis with respect to the negative dataset
Coverage TP TN FP FN Accuracy Sensitivity Specificity
St 0.21 134 44 40 13 0.77 0.91 0.52
Pfam 0.81 480 117 280 23 0.67 0.95 0.29
St U Pfam 0.87 490 145 291 35 0.66 0.93 0.33
St ∩ Pfam 0.15 124 16 29 1 0.82 0.99 0.36
Coverage, accuracy, sensitivity and specificity of the different strategies and their combinations (U = union and ∩ = intersection) with respect to the negative
dataset. Pfam, completeness of Pfam domains; St, structural plausibility. The definition of the other parameters is reported in Materials and methods. FN, false
negative; FP, false positive; TN, true negative; TP, true positive.
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remaining genes, 31,618 are classified as non-protein
coding according to the Ensembl annotations. In the
remaining genes, we found 7,467 isoforms differing only
for their untranslated regulatory regions from other iso-
forms in the same gene, and these were removed. We
also discarded an additional 1,844 genes that were left
with only one isoform. At this stage the dataset of alter-
native spliced isoforms contains 60,568 isoforms
encoded by 13,980 genes.
Taken together, these latter isoforms contain 278,155
exons in their coding sequences identified by a unique
Ensembl exon ID. These exons were classified as present
in all transcripts of a gene (constitutive, 20% of the total),
in a subset of the gene transcripts (semi-constitutive,
49%), or in a single transcript only (specific, 12%). Cases
of semi-constitutive exons with parts of their sequence
partially overlapping with another exon were classified in
a separated category (partially overlapping, 19%).
Mapping of proteomic peptides on the human AS
isoforms
Proteomics data were retrieved from the PeptideAtlas
database [13]. PeptideAtlas organizes its data into builds
centered on a particular species or tissue. We used the
May 2010 human build [22], which contains 71,303 dif-
ferent peptides ranging in size from 7 to 66 (mean 17);
these were unambiguously mapped to human Ensembl57
proteins. We selected only those peptides classified by
PeptideAtlas as non-exon spanning. Of these, 39,956
match isoforms included in our dataset. We classified
11,005 peptides that unambiguously identify one protein
isoform by mapping to a specific exon or to a specific
part of partially overlapping exons as ‘specific’ peptides.
Peptides that map into semi-constitutive exons, constitu-
tive exons or non-specific parts of partially overlapping
exons were classified as ‘unspecific’ peptides.
Building of the positive, negative and unknown datasets
The noAS positive dataset was built by selecting the
products of all non-alternatively spliced genes that are
unambiguously identified by PeptideAtlas peptides and
contains 865 gene products identified by 4,589 peptides.
All the isoforms produced by AS that are unambigu-
ously identified by specific PeptideAtlas peptides (576
isoforms identified by 2,546 peptides) were considered
for inclusion in the ASPos dataset. Out of all remaining
isoforms, those having specific exons (or specific exon
regions in partially overlapping exons) but that were not
identified by any PeptideAtlas peptide, although they
could in principle be detected according to the Peptide-
Sieve algorithm [16], were considered for inclusion in
the unknown dataset (782 isoforms). In detail, the
sequences of the isoforms in the unknown dataset were
submitted to the PeptideSieve algorithm, which predicts
the likelihood of the peptide being observed in a proteo-
mics experiment, taking into account ionization and
missed cleavage propensity. The program first performs
an in silico digestion of the protein and then computes
for each peptide a list of physical and chemical descrip-
tors. Next, it scores the likelihood that each peptide is
observed in one of the four proteomics platforms
(PAGE MALDI, PAGE ESI, ICAT ESI, MUDPIT ESI).
An unknown isoform is considered detectable in a pro-
teomics experiment if at least one of its peptides, origi-
nating from its specific regions, has a score of at least
0.5 (the default lower limit score in PeptideSieve). When
used as described above, PeptideSieve has an expected
accuracy above 85%. When more than one identified or
not identified isoform was present in the same gene, we
included only the shortest one of the ASPos dataset and
the longest one of the unknown dataset. At the end of
the procedure the ASPos and unknown datasets
included 555 isoforms each.
To obtain the negative dataset, we considered tran-
scripts annotated as non-coding present in regions of
t h eg e n o m ec o n t a i n i n ga tl east one coding transcript
(we did not include transcripts undergoing nonsense
mediated decay), translated their sequence starting from
the first AUG and continuing until a stop codon was
encountered, and selected the longest 555 translated
sequences. The average lengths of members of the data-
sets are 436 (noASPos), 694 (ASPos), 345 (unknown)
and 485 (negative).
Structural characterization of the isoform datasets
We built structural models by homology for each iso-
form in our datasets for which the native structure is
unknown, and for which a suitable template covering
more than 90% of the sequence could be found.
HHsearch 1.1.5 [23] was used to search for possible
structural templates (default parameters) and for
obtaining the sequence alignment between the target
and its putative templates. The resource builds a
HMM of the target protein family and compares it to
the HMMs representing a set of non-redundant
families of proteins of known structure (sequence
identity between any pair below 70%). Model building
was performed using a local version of Modeller9v8
[24] (default parameters). Models were considered
structurally plausible if there is a deletion with respect
to the template and the distance between the two resi-
dues on either side is larger than 15Å; if there is an
i n s e r t i o no fm o r et h a nt h r e er e s i d u e si nt h ec o r eo f
the protein, that is, between two residues whose sol-
vent accessibility calculated with POPS [25] is lower
than 5Å
2; if the packing efficiency of the resulting
model computed using the OS software [26] is below
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not; and if the ‘packing-eff’ computed using the NUC-
PROT package [27] is below 25.9, while that of the
template used for modeling is not. The thresholds for
POPS, Packing-eff and OS tools were derived by run-
ning the programs on 4,122 monomeric proteins
solved by X-ray crystallography at a resolution better
than 2Å. The chosen thresholds, 25.5 for POPS values,
25.9 for Packing-eff values and 0.54 for OS values,
correspond to two standard deviations from the aver-
age (data not shown).
Functional domain characterization of the isoform
datasets
We mapped Pfam domains [11] on the protein
sequences of the isoforms in the datasets, using the
batch search utility available through the Pfam web
interface, using Pfam-A families and an E-value below
10E-5. For each domain, we computed the coverage of
the HMM representing the domain: all domains
assigned to an isoform whose length covers less than
70% of the corresponding HMM were considered trun-
cated. This threshold was chosen by evaluating the
HMM coverage in a set of protein sequences for which
the structure is known. We extracted 3,859 monomeric
structures with less than 30% sequence identity from
PDB [20]. For every protein, the corresponding Uniprot
sequence was retrieved and Pfam domains were assigned
according to the criteria described above; 93% of Pfam
domains have a coverage between 0.70 and 1.0 in these
sequences (data not shown).
Mapping of Swiss-Prot features on the isoform datasets
Active site residues as annotated in Swiss-Prot (release
57, March 2009) were mapped on all isoforms encoded
b yag e n eu s i n gt h eE n s e m b lperl APIs and using in-
house developed tools.
Evaluation of transcriptomic expression
Exon-level isoform expression was extracted from Affy-
metrix Exon 1.0 ST Array public datasets [28]. The pro-
filed human tissues include breast, cerebellum, heart,
kidney, liver, muscle, pancreas, prostate, spleen, testis,
and thyroid. RNA-normalized probe-set expression
levels, computed using the Affymetrix Power Tools
(APT), are available from the Affymetrix web site. We
were able to retrieve isoform-specific expression levels
for 728 and 532 isoforms of the noASPos and ASPos
datasets, respectively, and 264 isoforms of the unknown
dataset. Probe set expression levels were computed as
the median of normalized expression values in the 11
tissues in the panel. Isoform expression is estimated as
the median expression of all probe sets falling in the iso-
form-specific regions.
Data analysis
We used the following definitions: true positive (TP) -
an isoform in the positive dataset for which the consid-
ered descriptor is consistent with the hypothesis of the
isoform being functional (that is, structurally plausible,
or not containing truncated domains, or containing an
active or binding site); false negative (FN) - a positive
set isoform for which a descriptor suggests loss of func-
tionality (that is, structurally not plausible, or containing
a truncated domain, or missing active sites present in
some other isoform of the same gene); false positive
(FP) - an unknown or negative set isoform for which
the considered descriptor is consistent with the hypoth-
esis of the isoform being functional; true negative
(TN) - an unknown or negative set isoform for which a
descriptor suggests loss of functionality. We can use the
confusion matrix originated by the values of TP, FN, FP,
TN to evaluate how well each descriptor (and all their
intersections and unions) is able to discriminate between
isoforms in the datasets, using the commonly used mea-
sures accuracy (ratio between correct predictions TP +
TN and total predictions TP + FN + FP + TN), sensitiv-
ity (ratio between correct positive predictions TP and
total predictions in the positive dataset TP + FN), and
specificity (ratio between correct negative predictions
TN and total predictions in the negative or unknown
dataset TN + FP). Since each descriptor can be applied
only to a subset of the total isoforms (for example, not
all isoforms can be modeled, not all isoforms have Pfam
domains, and not all isoforms have an annotated active
site), the coverage of each descriptor (defined as the
number of isoforms to which the descriptor can be
applied over the total number of isoforms under exami-
nation) is highly variable. The union of two descriptors,
or of all three of them, obviously increases the coverage
at the cost, in some cases, of accuracy. When consider-
ing the union of two or three descriptors, one must take
into account that a number of isoforms can have discor-
dant descriptors. For example, a given isoform of the
positive dataset can be structurally plausible, thus having
one truncated domain, and therefore it is a TP from the
point of view of the structural descriptor ad a FN for
the domain integrity descriptor. In all these cases we
counted these isoforms as FN (or as TN for isoforms
belonging to the negative or unknown dataset).
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